Supplementary Table 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Fujisawa, Takao; Imai, Mitsuho; Shibuki, Taro; Iida, Naoko; Ozaki, Hiroshi; Nonomura, Norio; Morizane, Chigusa; Iwata, Hiroji; Okano, Susumu; Yamagami, Wataru; Yamazaki, Naoya; Kadowaki, Shigenori; Taniguchi, Hiroya; Ueno, Makoto; Boku, Shogen; Oki, Eiji; Komatsu, Yoshito; Yuki, Satoshi; Makiyama, Akitaka; Otsuka, Tomoyuki; Hara, Hiroki; Okano, Naohiro; Nishina, Tomohiro; Sakamoto, Yasutoshi; Miki, Izumi; Kobayashi, Shin; Yuda, Junichiro; Kageyama, Shun-Ichiro; Nagamine, Michiko; Sakashita, Shingo; Sakamoto, Naoya; Yamashita, Riu; Koga, Yoshikatsu; Bando, Hideaki; Ishii, Genichiro; Kuwata, Takeshi; Park, Woong-Yang; Ohtsu, Atsushi; Yoshino, Takayuki

doi:10.1158/2159-8290.27434191

Supplementary Table 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

journal contribution

posted on 2024-11-01, 07:21 authored by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Hiroya Taniguchi, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Tomoyuki Otsuka, Hiroki Hara, Naohiro Okano, Tomohiro Nishina, Yasutoshi Sakamoto, Izumi Miki, Shin Kobayashi, Junichiro Yuda, Shun-Ichiro Kageyama, Michiko Nagamine, Shingo Sakashita, Naoya Sakamoto, Riu Yamashita, Yoshikatsu Koga, Hideaki Bando, Genichiro Ishii, Takeshi Kuwata, Woong-Yang Park, Atsushi Ohtsu, Takayuki Yoshino

Cox multivariate analysis of overall survival

History

ARTICLE ABSTRACT

The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence–driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective drugs to patients. Concurrently, studies assessing molecular residual disease–based precision medicine for resectable solid tumors, including CIRCULATE-Japan, are ongoing. The substantial data generated by these platforms are stored within a state-of-the-art supercomputing infrastructure, VAPOR CONE. Since 2015, our project has registered over 24,000 patients as of December 2023. Among 16,144 patients with advanced solid tumors enrolled in MONSTAR-SCREEN projects, 5.0% have participated in matched clinical trials, demonstrating a 29.2% objective response rate and 14.8-month median survival (95% CI, 13.4–16.3) for patients treated in the matched clinical trials. Notably, patients who received matched therapy demonstrated significantly prolonged overall survival compared with those who did not (hazard ratio 0.77; 95% confidence interval, 0.71–0.83).Significance: Our nationwide molecular profiling initiative played pivotal roles in facilitating the enrollment of patients with advanced solid tumors into matched clinical trials and highlighted the substantial survival benefits of patients treated with matched therapy. We aim to facilitate an industry–academia data-sharing infrastructure ecosystem, fostering new drug discovery paradigms and precision medicine.